Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zoledronic acid for erosive psoriatic arthritis
ACTRN12605000583640Phase 2Recruiting
- Sponsor
- The University of Auckland
- Start
- Aug 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in psoriatic arthritis (PsA) comparing Zoledronic acid with Placebo (2 arms). Primary endpoints: Change in bone erosion on MRI and Change in bone edema score on MRI. Started Aug 2005; status: recruiting.
02
Drugs
zoledronic acid
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on ACTRN12605000583640.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12605000583640.